Oligonucleotide Conjugation Kits Market Size, Share & Industry Analysis, By Product (Amine-reactive Conjugation Kits, Click-chemistry Conjugation Kits, Pre-activated Oligo Conjugation Kits, and Others), By Type (Antibody Oligonucleotide Conjugation, Peptide Oligonucleotide Conjugation, Protein Oligonucleotide Conjugation, Nanoparticles Oligonucleotide Conjugation, and Others), By Application (Therapeutic, Diagnostic, and Research), By End User (Pharmaceutical and Biotechnology Companies, Research and Academic Institutes, Diagnostics Centers, and Others), and Regional Forecast, 2026-2034

The global oligonucleotide conjugation kits market size was valued at USD 300 million and is projected to reach USD 7900 million by 2032, exhibiting a CAGR of 13.5% during the forecast period.

The market is anticipated to expand in the upcoming years owing to the increasing use of oligonucleotide therapeutics, along with advancements in diagnostic and research tools. Technological advancements in the conjugation of nanoparticles to create multifunctional complexes for imaging, therapy, and detection are expected to propel market growth further. Moreover, strategic collaborations among key companies are expected to drive market growth by expanding the existing applications and advancing product offerings.

• For instance, in June 2022, Almac Diagnostic Services collaborated with AstraZeneca to develop and commercialize multiple companion diagnostic (CDx) products. Such developments are expected to drive the market growth.

Furthermore, strategic activities such as research and development, collaborations, mergers, and acquisitions of key companies are anticipated to drive the market's growth over the upcoming years.

Oligonucleotide Conjugation Kits Market Driver

Expanding Oligonucleotide Therapeutics Pipeline to Drive the Market Growth

The expanding oligonucleotide therapeutics pipeline is a key driver accelerating the growth of the global oligonucleotide conjugation kits market. These advanced therapeutics rely heavily on conjugation technologies to improve targeted delivery, cellular uptake, stability, and bioavailability. Oligonucleotide conjugation kits play a crucial role in preclinical and formulation stages, enabling researchers to efficiently attach ligands, antibodies, peptides, or polymers to oligonucleotides for enhanced therapeutic performance.

As pharmaceutical pipelines expand, the demand for high-performance conjugation kits that simplify workflows continues to rise, driving market growth.

• For instance, in December 2022, GSK plc collaborated with Wave Life Sciences Ltd. to advance oligonucleotide therapeutics, including Wave’s preclinical RNA editing programme targeting alpha-1 antitrypsin deficiency (AATD), WVE-006. Such initiatives are expected to lead to an increasing demand and boost market growth.

Download Free sample to learn more about this report.

According to an article published in May 2019, titled ‘A Concise, Modular Antibody–Oligonucleotide Conjugation Strategy Based on Disuccinimidyl Ester Activation Chemistry’, conjugation yields determined for the three representative commercial antibodies were 85.7, 82.8, and 79.1 % for anti-CTSB, anti-Myc, and anti-FAAH, respectively.

Oligonucleotide Conjugation Kits Market Restraint

Lack of Standardization and Reproducibility across Kit Platforms to Hamper Product Adoption

One of the significant factors restraining market growth is the limited standardization of conjugation chemistries, such as linker systems and reaction parameters, across different kit manufacturers. The lack of uniform protocols often leads to variability in reaction efficiency, yield, and conjugate stability, which can affect data reliability in laboratory settings.

• For example, in November 2020, The Journal of Organic Chemistry reported and summarized the challenges in oligonucleotide synthesis, purification, and isolation, such as high costs and a lack of standardization. Such factors may hamper the adoption of these oligonucleotide conjugation kits.

Oligonucleotide Conjugation Kits Market Opportunity

Technological Advancements in Conjugation Chemistry to Offer Lucrative Growth Opportunities

The rise of single-cell sequencing and proteomics presents a lucrative market growth opportunity for developers of oligonucleotide conjugation kits. These emerging research areas heavily depend on antibody–oligonucleotide conjugates (AOCs) for various applications such as barcode tagging and multiplex molecular detection. The development of rapid and high-throughput conjugation kits tailored for multi-omic workflows eases the process and offers a market growth opportunity.

• For instance, in January 2025, Abcam launched its Lightning-Link Feature Barcode Oligonucleotide Conjugation Kits, designed to accelerate spatial biology and single-cell multiomic studies by allowing rapid, one-step labeling of antibodies with DNA barcodes.

Segmentation

Key Insights

The report covers the following key insights:

• Regulatory Scenarios, By Key Countries/Regions
• Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, and Others)
• New Product Launches, By Key Players
• Technological Advancements in Oligonucleotide Conjugation Kits

Analysis by Product

Based on product, the global oligonucleotide conjugation kits market is segmented into amine-reactive conjugation kits, click-chemistry conjugation kits, pre-activated oligo conjugation kits, and others.

Among these, the click-chemistry conjugation kits segment dominated the global oligonucleotide conjugation kits market. This dominance is primarily attributed to the high efficiency, specificity, and biocompatibility offered by click-chemistry reactions. These chemistries enable rapid, site-specific, and high-yield conjugation under mild conditions, minimizing byproducts and preserving biomolecule functionality. The growing demand for precision molecular labeling, multiomic research, and targeted oligonucleotide therapeutics continues to propel the preference for click-chemistry kits.

• For Instance, in September 2025, Secarna Pharmaceuticals GmbH & Co. KG collaborated with VERAXA Biotech to develop next-generation antibody oligonucleotide conjugates (AOCs). The combination of both technology platforms aims to unlock novel targeted therapies for the treatment of autoimmune and chronic immune diseases. The company utilized its technology suite, including a click chemistry conjugation platform, to design and generate highly efficacious, uniform, and safe AOCs.

Analysis by Type

Based on type, the market is classified into antibody oligonucleotide conjugation, peptide oligonucleotide conjugation, protein oligonucleotide conjugation, nanoparticles oligonucleotide conjugation, and others.

Among these, the antibody oligonucleotide conjugation segment is projected to dominate the market during the forecast period. This dominance is primarily driven by the rapid adoption of antibody oligo conjugates (AOCs) in advanced research, diagnostic, and therapeutic applications. With the expanding application of these oligonucleotides in therapeutics, the segmental share is expected to grow significantly.

• For instance, in November 2025, Novartis AG acquired Avidity Biosciences, Inc. The acquisition enabled the company to deliver a novel class of RNA therapeutics, called Antibody Oligonucleotide Conjugates (AOCs), for serious, genetic neuromuscular diseases. These factors are expected to drive the segmental growth.

Analysis by Application

Based on application, the market is segmented into therapeutic, diagnostic, and research.

Among these, the research segment is expected to generate a significant revenue share in the global oligonucleotide conjugation kits market. The wide applications of these kits in molecular biology, proteomics, and single-cell analysis workflows, which are essential for labeling, detection, and multiplexing, are expected to drive segmental growth.

• For instance, in May 2025, Amerigo Scientific introduced its expanding line of cell proliferation and viability assay kits, which offer performance bound to revolutionize cell-based assays for drug discovery researchers, immunologists, and regenerative medicine specialists. Such factors drive the growth of the segment.

Analysis by End User

The market is fragmented into pharmaceutical and biotechnology companies, research and academic institutes, diagnostics centers, and others in terms of end-user.

The pharmaceutical and biotechnology companies segment is expected to hold a significant share in the global oligonucleotide conjugation kits market. The segment's dominance is attributed to its extensive investment in oligonucleotide-based drug discovery. The increasing number of clinical trials involving oligonucleotide conjugates and antibody oligonucleotide conjugates (AOCs) have accelerated the adoption of specialized conjugation kits in R&D and preclinical stages.

• For instance, in October 2023, Waters Corporation launched OligoWorks SPE (solid-phase extraction) Kits and components to enhance sample preparation for LC-MS-based bioanalytical quantification of therapeutic oligonucleotides. The development aimed to aid pharmaceutical and biopharmaceutical companies in developing oligonucleotide therapeutics that reduce the need for repeat experiments.

Regional Analysis

Request for Customization   to gain extensive market insights.

On the basis of region, the market has been studied across North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.

North America accounted for approximately 48% of the global oligonucleotide conjugation kits market in 2024. The dominance of the region is due to high strong presence of oligonucleotide drug developers and advanced biotechnology infrastructure. Additionally, increasing investment in RNA and gene therapy programs is expected to create a surge in the demand for reliable conjugation solutions. Furthermore, increasing investment in the expansion of manufacturing capacity is expected to drive the market's growth.

• For instance, in October 2024, Merck KGaA invested USD 75.8 million to expand its manufacturing of Antibody Drug Conjugates (ADCs) for novel cancer therapies. These factors are expected to heighten the demand for oligonucleotide conjugation kits and drive market growth in the region.

Europe is expected to grow with a significant CAGR over the forecast period due to expanding application of precision medicine, leading to greater adoption of conjugation kits for research and drug development. Moreover, increasing investment in research and development as well as the expansion of manufacturing capabilities are expected to drive product demand in the region.

• For instance, in October 2025, BioSpring collaborated with Luxna Biotech Co., Ltd., to enable the manufacturing of oligonucleotides incorporating Luxna’s proprietary Xeno Nucleic Acid (XNA) amidites.

Asia Pacific is expected to grow at a stable CAGR during the forecast period. The region is expected to experience growth due to the increasing adoption of conjugation kits for research and drug development. Moreover, government-backed funding for oligonucleotide therapeutics and increasing approvals by regulatory bodies in the region for therapeutic conjugates are expected to drive the demand.

• For instance, in April 2025, Avidity Biosciences, Inc. received orphan drug designation from the Japan Ministry of Health, Labour and Welfare (MHLW) for delpacibart etedesiran (del-desiran), an antibody oligonucleotide conjugate for the treatment of myotonic dystrophy type 1 (DM1). The adoption of antibody oligonucleotide conjugates for therapeutics is expected to increase demand for these oligonucleotide conjugates.

Key Players covered

The global oligonucleotide conjugation kits market is consolidated, with a few players capturing a significant market share.

The report includes the profiles of the following key players.

• Abcam Limited. (U.K.)
• Vector Laboratories, Inc. (U.S.)
• BroadPharm (U.S.)
• RayBiotech, Inc. (U.S.)
• Creative Biogene (U.S.)
• AAT Bioquest, Inc. (U.S.)
• Kaneka Eurogentec S.A. (Belgium)
• AlphaThera (U.S.)
• CellMosaic (U.S.)
• VERAXA (Germany)

Key Industry Developments

• June 2025: Amerigo Scientific offered PerKits drug conjugation kits to simplify and optimize the conjugation of small-molecule drugs to biomolecules. These drug conjugations emerged as a means for developing targeted therapies with the growing demand for robust and reliable conjugation solutions.
• May 2024: QIAGEN collaborated with Myriad Genetics to develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. The development aimed to support research into personalized medicine in multiple solid tumor types, including ovarian cancer.